Resverlogix Corporation

Zenith Epigenetics Corp.

Henrik C Hansen

Fabrizio S Chiacchia

Norman C W Wong

David Robert McCaffrey

Joseph E L Tucker

Ewelina B Kulikowski

Joseph E Tucker

Norman C Wong

David Mccaffrey

Gregory Steven Wagner

George Yiannikouros

Jiahui Chen

Jan Johansson

Mark T Edgar

Shubham P Chopade

Christopher R A Halliday

Dean E Gilham

Janakiram Rao Citineni

Sylwia Wasiak

Robert P Short

Feng Wen

Xianghui Wen

Sarah C Attwell

Kevin G McLure

Janakiram R Citineni

Jan O Johansson

Norman CW Wong

George P Yiannikouros

Laura Tsujikawa

Christopher Ra Halliday

Dean Gilham

The invention relates to solid crystalline forms of Compound (I), such as e.g., Form VII, including pharmaceutical compositions thereof and processes for preparing crystalline Compound (I), Form VII. Compound (I) modulates or inhibits the activity of BET bromodomain-containing proteins, and is useful in the treatment of diseases such as cancer, inflammatory and cardiovascular diseases.

Method of manufacturing a solid form of a BET bromodomain inhibitor

Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

Anti-inflammatory agents

The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.

Compositions and therapeutic methods for the treatment of complement-associated diseases

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Compounds for the prevention and treatment of cardiovascular diseases

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds. Formula (I) 

Compounds for the prevention and treatment of cardiovascular disease

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices

The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases

Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases

The present disclosure relates to methods for preparing compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and in the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. 

Methods of preparing quinazolinone derivatives

Growing community of inventors

Calgary, Canada

Henrik C Hansen